New hope for Tough-to-Treat lung cancer?
NCT ID NCT05469178
Summary
This study tested whether adding an experimental drug called bemcentinib to standard chemotherapy and immunotherapy is safe and effective for people with advanced non-small cell lung cancer. It focused on patients who had not received prior treatment and included a group with a specific genetic mutation (STK11) that often makes cancer harder to treat. The main goals were to find the safest dose and see if the combination could shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azienda Ospedaliero-Universitaria Policlinico S. Orsola-Malpighi
Bologna, 40138, Italy
-
Centre Antoine Lacassagne
Nice, 6189, France
-
Duke University Medical Center - Duke Cancer Center
Durham, North Carolina, 27710, United States
-
Fejer County St. Gyorgy Hospital
Székesfehérvár, 8000, Hungary
-
Fundacion Instituto Valenciano de Oncologia (FIVO)
Valencia, 46009, Spain
-
General Hospital of Athens Alexandra, Department of the Clinical Therapeutics, Medical Oncology Unit
Athens, 11528, Greece
-
Henry Dunant Hospital Center, 4th Oncology Department
Athens, 115 26, Greece
-
Hospital Clinico Universitario de Valencia
Valencia, 46010, Spain
-
Hospital Universitari Germans Trias i Pujol
Badalona, 8916, Spain
-
Hospital Universitario Fundacion Jimenez Diaz
Madrid, 28040, Spain
-
Hospital Universitario La Paz
Madrid, 28046, Spain
-
Hospital Universitario Ramon y Cajal
Madrid, 28034, Spain
-
Hospital Universitario Vall d'Hebron
Barcelona, 8035, Spain
-
Hôpital Europeen Georges Pompidou (HEGP), Service de cancérologie
Paris, 75015, France
-
Hôpital prive du Confluent SAS, Departement d'oncologie
Nantes, 44277, France
-
IFO Regina Elena
Rome, 144, Italy
-
IRCCS - Istituto Europeo di Oncologia IEO
Milan, 20141, Italy
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Institut Gustave Roussy, Service de médecine
Villejuif, 94805, France
-
Instytut Centrum Zdrowia Matki Polki (ICZMP)
Lodz, 93-338, Poland
-
MD Anderson Cancer Center, Oncology service
Madrid, 28033, Spain
-
Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland
Baltimore, Maryland, 21201, United States
-
MedPolonia Sp z oo
Poznan, 60693, Poland
-
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida, 33140, United States
-
Orszagos Koranyi Pulmonologiai Intezet
Budapest, 1121, Hungary
-
Ospedale San Luca
Lucca, 55100, Italy
-
Semmelweis University- Department of Pulmonology
Budapest, 1083, Hungary
-
Sotiria General Hospital of Chest Diseases, 3rd Department of Internal Medicine, Oncology Unit
Athens, 115 27, Greece
-
Tennessee Oncology PLLC
Nashville, Tennessee, 37203, United States
-
UT Southwestern Medical Center
Dallas, Texas, 75390, United States
-
University General Hospital of Larissa, Oncology Clinic
Larissa, 41110, Greece
-
University of Chicago
Chicago, Illinois, 60637, United States
-
Uniwersytecki Szpital Kliniczny Nr 4 w Lublinie
Lublin, 20090, Poland
-
Uniwersytecki Szpital Kliniczny w Bialymstoku, II Klinika Chorob Pluc, raka płuca i chorób wewnętrznych
Bialystok, 15-540, Poland
Conditions
Explore the condition pages connected to this study.